Kintara Therapeutics Inc (KTRA)

[axelvento]

buy.....

In other DelMar Pharmaceuticals news, CEO Saiid Zarrabian acquired 60,900 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was purchased at an average price of $0.82 per share, for a total transaction of $49,938.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders acquired 108,400 shares of company stock valued at $89,713 in the last quarter.

A number of large investors have recently added to or reduced their stakes in DMPI. Franklin Resources Inc. purchased a new position in DelMar Pharmaceuticals in the second quarter worth $2,477,000. Sabby Management LLC purchased a new position in DelMar Pharmaceuticals in the second quarter worth $1,484,000. Finally, Susquehanna International Group LLP purchased a new position in DelMar Pharmaceuticals in the third quarter worth $306,000. Hedge funds and other institutional investors own 16.91% of the company’s stock.